BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Thyroid cancer AND ATM, TELO1, 472, ENSG00000149311, TEL1, ATD, ATE, DKFZp781A0353, AT1, Q13315, MGC74674, ATDC, ATC, ATA AND Prognosis
346 results:

  • 1. Development and validation of prediction models for papillary thyroid cancer structural recurrence using machine learning approaches.
    Wang H; Zhang C; Li Q; Tian T; Huang R; Qiu J; Tian R
    BMC Cancer; 2024 Apr; 24(1):427. PubMed ID: 38589799
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Predictors of recurrence after total thyroidectomy in 1,611 patients with papillary thyroid carcinoma: postoperative stimulated serum thyroglobulin and ata initial and dynamic risk assessment.
    Ywata de Carvalho A; Kohler HF; Ywata de Carvalho CCG; Vartanian JG; Kowalski LP
    Arch Endocrinol Metab; 2024 Apr; 68():e220506. PubMed ID: 38578436
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. A distinct tumor microenvironment makes anaplastic thyroid cancer more lethal but immunotherapy sensitive than papillary thyroid cancer.
    Han PZ; Ye WD; Yu PC; Tan LC; Shi X; Chen XF; He C; Hu JQ; Wei WJ; Lu ZW; Qu N; Wang Y; Ji QH; Ji DM; Wang YL
    JCI Insight; 2024 Mar; 9(8):. PubMed ID: 38478516
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. The value of multimodal treatment in anaplastic thyroid cancer patients with distant metastasis.
    Guo H; Lin H
    BMC Surg; 2024 Mar; 24(1):79. PubMed ID: 38438944
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Second radioiodine treatment in patients with differentiated thyroid carcinoma: Causes and effects.
    Sicilia Pozo MLN; Pena Pardo FJ; Amo Salas M; Cruz Montijano M; Torres Hernández J; Padilla Bermejo A; Montalbán Méndez C; Zhao Montero M; Soriano Castrejón Á; García Vicente AM
    Endocrinol Diabetes Nutr (Engl Ed); 2024 Jan; 71(1):4-11. PubMed ID: 38388076
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Evaluation of the correlation of neutrophil/lymphocyte ratio with prognostic classification systems in papillary thyroid carcinoma patients.
    Yildiz EO; Işcen K; Kaya F; Güney OA; Ulukent SC
    Medicine (Baltimore); 2024 Feb; 103(5):e37210. PubMed ID: 38306518
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Progress in diagnosing and treating thyroid squamous cell carcinoma under the 5th edition of WHO classification.
    Ding W; Gao X; Ran X
    Front Endocrinol (Lausanne); 2023; 14():1273472. PubMed ID: 38303977
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. [TRIP13 Enhances Radioresistance of Lung Adenocarcinoma Cells 
through the Homologous Recombination Pathway].
    Ge S; Gu R; Yang X; Xu C; Wang S; Zhu G
    Zhongguo Fei Ai Za Zhi; 2024 Jan; 27(1):1-12. PubMed ID: 38296621
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Circulating immunophenotypes are potentially prognostic in follicular cell-derived thyroid cancer.
    Kotwal A; Gustafson MP; Bornschlegl S; Dietz AB; Delivanis D; Ryder M
    Front Immunol; 2023; 14():1325343. PubMed ID: 38235146
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Association Between a History of Breast cancer and Decreased thyroid cancer-specific Mortality.
    Lin S; Wang Z; Xing M
    J Clin Endocrinol Metab; 2024 Apr; 109(5):1222-1230. PubMed ID: 38064679
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Brusatol attenuated proliferation and invasion induced by KRAS in differentiated thyroid cancer through inhibiting Nrf2.
    Gong Z; Xue L; Vlantis AC; van Hasselt CA; Chan JYK; Fang J; Wang R; Yang Y; Li D; Zeng X; Tong MCF; Chen GG
    J Endocrinol Invest; 2024 May; 47(5):1271-1280. PubMed ID: 38062319
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Immunological characteristics of immunogenic cell death genes and malignant progression driving roles of TLR4 in anaplastic thyroid carcinoma.
    Xu T; Zhu C; Song F; Zhang W; Yuan M; Pan Z; Huang P
    BMC Cancer; 2023 Nov; 23(1):1131. PubMed ID: 37990304
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. HOXD9/miR-451a/PSMB8 axis is implicated in the regulation of cell proliferation and metastasis via PI3K/AKT signaling pathway in human anaplastic thyroid carcinoma.
    Zhong Y; Yu F; Yang L; Wang Y; Liu L; Jia C; Cai H; Yang J; Sheng S; Lv Z; Weng L; Wu B; Zhang X
    J Transl Med; 2023 Nov; 21(1):817. PubMed ID: 37974228
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. [Personalized approach to anaplastic thyroid carcinoma].
    Wächter S; Bartsch DK; Maurer E
    Chirurgie (Heidelb); 2024 Mar; 95(3):192-199. PubMed ID: 37973622
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Predictive risk factors for distant metastasis in pediatric differentiated thyroid cancer from Saudi Arabia.
    Parvathareddy SK; Siraj AK; Annaiyappanaidu P; Siraj N; Al-Rasheed M; Al-Haqawi W; Qadri Z; Siddiqui K; Al-Sobhi SS; Al-Dayel F; Al-Kuraya KS
    Front Endocrinol (Lausanne); 2023; 14():1228049. PubMed ID: 37867506
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Anaplastic thyroid cancer:Improved understanding of what remains a deadly disease.
    Cleere EF; Prunty S; O'Neill JP
    Surgeon; 2024 Feb; 22(1):e48-e53. PubMed ID: 37866980
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Factors Associated with Survival in Anaplastic thyroid Carcinoma: A Multicenter Study from the ENDOCAN-TUTHYREF Network.
    Jannin A; Giudici F; de la Fouchardière C; Al Ghuzlan A; Wassermann J; Chougnet CN; Drui D; Godbert Y; Ilouz F; Bardet S; Zanetta S; Roudaut N; Batisse Lignier M; Groussin L; Klein M; Zerdoud S; Lamartina L; Baudin E; Decaussin-Petrucci M; Leteurtre E; Borson Chazot F; Do Cao C; Borget I; Hadoux J;
    Thyroid; 2023 Oct; 33(10):1190-1200. PubMed ID: 37855745
    [No Abstract]    [Full Text] [Related]  

  • 18. BRAF
    Cao J; Chen B; Zhu X; Sun Y; Li X; Zhang W; Wang X
    Endocrine; 2024 Apr; 84(1):160-170. PubMed ID: 37851243
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. New Insights into Immune Cells and Immunotherapy for thyroid cancer.
    Tao Y; Li P; Feng C; Cao Y
    Immunol Invest; 2023 Nov; 52(8):1039-1064. PubMed ID: 37846977
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Customizing cancer treatment at the nanoscale: a focus on anaplastic thyroid cancer therapy.
    Wang J; Tan J; Wu B; Wu R; Han Y; Wang C; Gao Z; Jiang D; Xia X
    J Nanobiotechnology; 2023 Oct; 21(1):374. PubMed ID: 37833748
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 18.